Fertility preservation with the use of GnRH analogue in women undergoing chemotherapy for lymphoma: a systematic review and meta-analysis

Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network

“…Compelling evidence supports the benefit yielded by GnRHa administration in cancer patients in terms of reduced risk of CTh-induced premature ovarian failure (POF) (Del Mastro et al, 2011Lambertini et al, 2014;Lambertini, Ceppi, et al, 2015;Moore et al, 2015) and increased pregnancy rates (Del Mastro et al, 2011;Lambertini, Ceppi, et al, 2015;Matteo Lambertini et al, 2014Moore et al, 2015;Wong, O'Neill, Walsh, & Smith, 2013), with no negative impact on prognosis (Lambertini, Ceppi, et al, 2015). Despite the efficacy of this option in some cancer types, GnRHa remains controversial (Behringer et al, 2012;Blumenfeld, Zur, & Dann, 2015;Demeestere et al, 2016;Tavares, Senra, Talim, & Reis, 2016). While a protective effect has been demonstrated in breast cancer patients (Del Mastro et al, 2011, Blumenfeld et al, 2015, Blumenfeld & Evron, 2016, more studies are needed to confirm the protective role of GnRHa in patients with other types of cancer (Demeestere et al, 2016, reviewed in Lambertini, Horicks, Mastro, Partridge, & Demeestere, 2019.…”